IBtrol: The Science

IBtrol: The Science

Understanding IBS, the Gut Microbiome, and How IBtrol Supports Digestive Balance

The gut is a complex ecosystem. Over 100 trillion bacteria form a vast microbial community that works together, and alongside the immune system, to help support normal digestion, gut comfort, and overall health.

This microbial community is known as the gut microbiome.

In individuals living with irritable bowel syndrome (IBS), digestive symptoms can occur even when standard medical tests appear normal. IBS is therefore classified as a functional digestive disorder, meaning the issue relates to how the gut functions rather than structural abnormalities.

For many people, IBS symptoms such as abdominal discomfort, bloating, excess gas, and unpredictable bowel patterns can significantly impact daily life, confidence, and food choices.

The Role of the Gut Microbiome in IBS

Research suggests that the gut microbiome often differs in individuals with IBS compared to those without digestive concerns. This imbalance, known as dysbiosis, may influence gut motility, stool consistency, and communication between the gut and brain.

Changes in microbial activity can affect how quickly the large intestine moves contents through the digestive tract. This may contribute to alternating or irregular bowel habits as well as heightened sensitivity to digestive discomfort.

Symptoms of IBS can involve:

  • Abdominal pain or cramping
  • Bloating
  • Excess gas
  • Changes in bowel movement frequency
  • Variations in stool consistency

Supporting digestive balance and microbiome health is therefore an important focus for many individuals managing IBS symptoms.

A Targeted Nutritional Approach to Supporting IBS Symptoms

IBtrol was developed to help support digestive comfort while also addressing factors associated with microbiome imbalance.

  • The formulation is designed to help:
  • Support more regular bowel patterns
  • Promote a balanced gut microbial environment
  • Help manage symptoms such as bloating and gas
  • Support digestive resilience

Although IBtrol was formulated specifically with IBS symptom support in mind, it may also be helpful for individuals experiencing occasional digestive sensitivity or food-related gut discomfort.

Expert Formulation Rooted in Clinical Experience

IBtrol was developed by UK gut health expert Dr. Bridgette Wilson in collaboration with Medtrition, a medical nutrition company based in Lancaster, Pennsylvania that has focused on evidence-based nutritional solutions since 1986.

With over two decades of clinical and research experience in IBS, Dr. Wilson designed IBtrol to support a range of IBS symptom patterns.

Three Evidence-Based Ingredients Working Together

IBtrol combines three clinically researched components at targeted daily doses:

  • Premium blonde psyllium fiber
  • Beta-galacto-oligosaccharide (b-GOS) prebiotic
  • A five-strain probiotic blend

Psyllium Fiber and Digestive Regularity

Clinical reviews suggest psyllium fiber may help support improvements in overall IBS symptoms, including abdominal discomfort and bowel pattern irregularity (Dimidi et al., 2020). Additional research has indicated that psyllium may assist in supporting more normalized bowel movements in individuals experiencing both loose and infrequent stools (Gill et al., 2021).

When consumed with adequate fluid, psyllium helps form a gel-like structure that can add bulk to stool and help manage excess fluid in the digestive tract. This dual action may help support digestive consistency without significantly increasing gas production in many individuals (So et al., 2021).

Daily intake of approximately 10 grams of psyllium has been associated with symptom improvements in clinical settings.

Prebiotic Support for Microbiome Balance

The patented beta-galacto-oligosaccharide (b-GOS) prebiotic included in IBtrol is among the most extensively studied prebiotics in functional digestive disorders.

Human clinical trials have demonstrated that targeted doses of b-GOS may help support reductions in IBS symptoms while promoting beneficial Bifidobacteria populations in the gut microbiome (Silk et al., 2009; Wilson et al., 2020; Vulevic et al., 2019; Huaman et al., 2018).

The 1.4-gram daily dose included in IBtrol was selected based on research demonstrating favorable digestive symptom outcomes.

Probiotics and Gut Microbial Diversity

IBtrol includes five clinically studied probiotic strains:

  • Bifidobacterium lactis BI-04
  • Bifidobacterium lactis Bi-07
  • Lactobacillus acidophilus NCFM
  • Lactobacillus paracasei Lpc-37
  • Bifidobacterium lactis HN019

Each strain has been evaluated in human research related to digestive health. This specific probiotic combination has also been studied in individuals with IBS.

In a clinical study involving 188 participants, daily supplementation with this formulation (12 billion CFU) was associated with improvements in bowel pattern consistency, digestive comfort, and overall symptom scores (Harris et al., 2022).

Why Combining Fiber, Prebiotics, and Probiotics Matters

While each ingredient has demonstrated benefits individually, IBS symptoms are often multifactorial.

  • Psyllium may help support bowel pattern regulation
  • Prebiotics may help nourish beneficial bacteria
  • Probiotics may help support microbial diversity and gut immune function

Together, these ingredients provide complementary mechanisms that may help support digestive balance more comprehensively than single-ingredient approaches.

Research exploring fiber-prebiotic combinations has also suggested that specific ratios of these components may help delay peak gas production — an effect observed in both laboratory modeling and human imaging studies.

Additional human research evaluating the psyllium-prebiotic combination reported improvements in digestive symptoms such as bloating, gas, incomplete evacuation, and fatigue after several weeks of use.

Evidence-Based Nutrition for Digestive Confidence

At Medtrition, the development of IBtrol was guided by a commitment to clinically supported nutrition.

By combining targeted fiber, prebiotic, and probiotic support — and grounding formulation decisions in expert research — IBtrol was designed to help individuals take a proactive approach to managing digestive discomfort and supporting long-term gut health.

Shop IBtrol direct: IBtrol® 3-in-1 IBS Support – Medtrition 

References:

  • Wilson, Bridgette, et al. "β-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal bifidobacteria." Official journal of the American College of Gastroenterology| ACG 115.6 (2020): 906-915. 
  • Shepherd, Susan J., et al. "Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence." Clinical gastroenterology and hepatology 6.7 (2008): 765-771.
  • Cox, Selina R., et al. "Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial." Journal of Crohn's and Colitis 11.12 (2017): 1420-1429.
  • Huaman, Jose-Walter, et al. "Effects of prebiotics vs a diet low in FODMAPs in patients with functional gut disorders." Gastroenterology 155.4 (2018): 1004-1007.
    Hustoft, T. N., et al. "Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome." Neurogastroenterology & Motility 29.4 (2017): e12969.
  • Staudacher, Heidi M., et al. "Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome." The Journal of nutrition 142.8 (2012): 1510-1518.
  • Staudacher, Heidi Maria, et al. "A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: a randomized controlled trial." Gastroenterology 153.4 (2017): 936-947.
  • Wilson, Bridgette, Selina R. Cox, and Kevin Whelan. "Challenges of the low FODMAP diet for managing irritable bowel syndrome and approaches to their minimisation and mitigation." Proceedings of the Nutrition Society 80.1 (2021): 19-28.
  • So, Daniel, et al. "Supplementing dietary fibers with a low FODMAP diet in irritable bowel syndrome: a randomized controlled crossover trial." Clinical Gastroenterology and Hepatology 20.9 (2022): 2112-2120.
  • Dimidi E, Whelan K. Food supplements and diet as treatment options in irritable bowel syndrome. Neurogastroenterology & Motility 2020;32:e13951.
  • Gill, Samantha K., et al. "Dietary fibre in gastrointestinal health and disease." Nature Reviews Gastroenterology & Hepatology 18.2 (2021): 101-116.
  • So D, Gibson PR, Muir JG, et al. Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine. Gut 2021;70:2383-2394.
  • Miller LE, Lehtoranta L, Lehtinen MJ. The Effect of Bifidobacterium animalis ssp. lactis HN019™ on cellular immune function in healthy elderly subjects: systematic review and meta-analysis. Nutrients. 2017;9:191.)
  • Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome-A systematic review. Gastroenterology. 2019;157(1):97–13. doi:10.1053/j.gastro.2019.03.049.
  • Silk, D. B. A., et al. "Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome." Alimentary pharmacology & therapeutics 29.5 (2009): 508-518.
  • Vulevic, Jelena, et al. "Effect of a prebiotic galactooligosaccharide mixture (B‐GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence." Neurogastroenterology & Motility 30.11 (2018): e13440.
  • Huaman, Jose-Walter, et al. "Effects of prebiotics vs a diet low in FODMAPs in patients with functional gut disorders." Gastroenterology 155.4 (2018): 1004-1007.
  • Harris, Lucinda A., et al. "An open-label, multicenter study to assess the efficacy and safety of a novel probiotic blend in patients with functional gastrointestinal symptoms." Journal of Clinical Gastroenterology 56.5 (2022): 444-451.